Back to Search
VINCENTE VALERO, M.D.
M.D.
Medical Oncology Physician
NPI: 1447355003IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
H1453(TX)
Education
OTHER
Class of 1980
Research & Publications (20)
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.
PMID 18381372·Ann Oncol·2008
3-trial
Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
PMID 12435294·Clin Breast Cancer·2002
6-review
Primary chemotherapy with docetaxel for the management of breast cancer.
PMID 12108896·Oncology (Williston Park)·2002
6-review
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
PMID 11552226·Semin Oncol·2001
6-review
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.
PMID 19602564·Ann Oncol·2010
8-other
Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.
PMID 19556811·Oncology·2009
3-trial
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
PMID 19364972·J Clin Oncol·2009
8-other
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
PMID 19451443·J Clin Oncol·2009
8-other
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
PMID 19435916·Cancer Res·2009
8-other
Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
PMID 19197997·Cancer·2009
8-other
Circulating tumor cells in metastatic inflammatory breast cancer.
PMID 19556320·Ann Oncol·2009
8-other
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.
PMID 18581139·J Cancer Res Clin Oncol·2009
4-observational
Granulocyte-macrophage colony-stimulating factor gene based therapy for acute limb ischemia in a mouse model.
PMID 19194978·J Gene Med·2009
7-preclinical
Efficient method for obtaining Lep(ob)/Lep(ob)-derived animal models using adipose tissue transplantations.
PMID 19528967·Int J Obes (Lond)·2009
7-preclinical
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.
PMID 19470724·Clin Cancer Res·2009
8-other
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
PMID 19047121·Clin Cancer Res·2008
3-trial
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
PMID 19010894·Cancer Res·2008
7-preclinical
A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects.
PMID 19050516·Plast Reconstr Surg·2008
6-review
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
PMID 18829560·Cancer Res·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1447355003
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile